Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAltitude Group Regulatory News (ALT)

Share Price Information for Altitude Group (ALT)

Share Price is delayed by 15 minutes
Get Live Data
20.50    0.50 (2.50%)
Bid:
20.00
Ask:
21.00
Spread: 1.00 (5.00%)
Market Cap: £14.99m
ALT Live PriceLast checked at - London Stock Exchange

Intraday Altitude Group Share Chart

Trading Update

25 Oct 2022 07:00

RNS Number : 9436D
Altitude Group PLC
25 October 2022
 

Altitude Group plc

("Altitude" or the "Company")

 

Trading Update

 

Altitude Group Reports Strong Trading Driven by Underlying Business Growth

Altitude Group plc (AIM: ALT), the operator of a leading marketplace for personalised products, today issues a trading update for the six months ended 30 September 2022 ("H1 23").

The Board is pleased to report the Group has delivered another excellent period of growth, driven by successes across all key Services and Merchanting programmes. Unaudited revenue for H1 23 is expected to be no less than c. £7.6 million (H1 22: £5.9 million) an increase of c.30%. As a result of the strong underlying business performance, an advantageous exchange rate and having not experienced any negative impact to date from the current macro-economic turbulence, we continue to trade well and expect to be at least in line with market expectations for the financial year to 31 March 2023*.

This continued growth is being driven by our strategic focus on and continuous development of both our Services and Merchanting programmes, which have delivered strong trading.

Our core systems and people infrastructure have been developed and are designed for continued scalable growth underpinning our long-term success. 

It is testament to the hard work of our team, our strong partner relationships, and our market leading customer proposition, that we are able to report such strong trading and continued growth. With continued focus on our strategy to scale the business and with the Company well placed for accelerated future growth, the Board remains confident in its positive outlook for the future.

 

We look forward to announcing our H1 23 interim results on 29 November 2022.

 

*External market consensus for the year ending 31 March 2023 is currently revenue of £13.9 million and adjusted EBITDA of £1.2 million.

 

For enquiries, please contact:

Altitude Group plc

Nichole Stella, Chief Executive Officer

Graham Feltham, Chief Financial Officer

 

Via Zeus Capital

Zeus (Nominated Adviser & Broker)

Dan Bate / David Foreman / James Edis (Investment Banking)

Dominic King (Corporate Broking)

Tel: 0203 829 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBKQBKFBDDFKB
Date   Source Headline
8th Jun 20267:00 amRNSDirector/PDMR Shareholding
1st Jun 20268:31 amRNSExercise & Grant of Options and TVR
17th Apr 20267:00 amRNSBoard Role Change
14th Apr 20263:25 pmRNSDirector/PDMR Dealing
9th Apr 202612:00 pmRNSDirector/PDMR Dealing
31st Mar 20267:00 amRNSTrading Update
5th Mar 20263:39 pmRNSDirector/PDMR Shareholding
5th Mar 20267:00 amRNSAppointment of Independent Non-Executive Director
10th Feb 202612:32 pmRNS-RAppointment of Chief Commercial Officer
4th Feb 20267:00 amRNSAppointment of Nominated Adviser and Sole Broker
19th Jan 20261:33 pmRNSPDMR Dealing
23rd Dec 20257:00 amRNSPDMR Dealing
23rd Dec 20257:00 amRNSPDMR Dealing
1st Dec 20259:01 amRNSPDMR Dealing
28th Nov 20257:00 amRNSChange of Registered Office
27th Nov 20254:57 pmRNSCorrection: Exercise & Grant of Options and TVR
27th Nov 20257:30 amRNSExercise & Grant of Options, PDMR Dealings and TVR
27th Nov 20257:00 amRNSInterim Results
11th Nov 20257:00 amRNSTrading Update, Board Change and Notice of Results
30th Oct 20257:00 amRNSHolding(s) in Company
26th Sep 20257:00 amRNSResult of AGM
12th Sep 20257:00 amRNSDirector/PDMR Dealing
11th Sep 20257:00 amRNSDirector/PDMR Dealing
10th Sep 20257:00 amRNSDirector/PDMR Dealing
8th Sep 20257:00 amRNSDirector/PDMR Dealing
5th Sep 20257:00 amRNSDirector/PDMR Dealing
15th Aug 20254:20 pmRNSChange of Venue for the 2025 AGM
7th Aug 20257:00 amRNSAudited Annual Results and Notice of AGM
30th Jul 20257:00 amRNSNotice of Results
15th Jul 20257:00 amRNSBoard Changes and Trading Update
23rd Jun 20257:00 amRNSAppointment of CFO
17th Jun 20257:00 amRNSBoard Change and Trading Update
15th May 20257:00 amRNSGrant of Options and PDMR Dealings
9th May 20255:50 pmRNSDirector/PDMR Dealing
9th Apr 20257:00 amRNSExercise of Options, Director Dealings and TVR
1st Apr 20257:00 amRNSDirector/PDMR Dealing
31st Mar 20257:00 amRNSTrading Update and New University Contract Awards
28th Mar 20257:00 amRNSChange of Registered Office
11th Mar 20257:00 amRNSDirector/PDMR Dealings
6th Mar 20257:00 amRNSDirectorate Change
3rd Dec 20247:00 amRNSInterim Results
15th Nov 20247:00 amRNSTrading Update and Notice of Results
8th Oct 20244:04 pmRNSHolding(s) in Company
23rd Sep 20244:47 pmRNSResult of AGM
6th Sep 202412:30 pmRNSPosting of Annual Report and Notice of AGM
30th Jul 20247:00 amRNSAudited Annual Results and Notice of AGM
23rd Jul 20247:00 amRNSFull Year Trading Update
3rd Jun 20249:28 amRNSExercise of Options, Director Dealings and TVR
20th May 20247:00 amRNSGrant of Options and PDMR Dealings
1st May 20247:00 amRNSPre-Close Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.